Microbion Corporation

Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to treat rare, chronic, and serious diseases. Our lead drug candidate, pravibismane, is the first drug in a new class recognized by the World Health Organization INN. Pravibismane has multiple novel modes of activity, including broad-spectrum potency against MDR pathogens, an unprecedented ability to prevent and eradicate biofilms, and the ability to modulate a critical cytokine involved in autoimmune and inflammatory diseases. Multiple pravibismane formulations are in clinical development to address the unmet needs of chronic lung disease, chronic wounds, and orthopedic infections. Collectively, these indications represent over $5B in peak annual sales potential for pravibismane in the US alone based on third-party forecasts. Pravibismane has been safe and well-tolerated in five clinical studies with over 325 human subjects while demonstrating clinical efficacy in Phase 1b/2a studies.